---
type: claim
domain: health
description: Combination of pharmacotherapy with digital behavioral programs achieves clinical-trial-level outcomes in real-world settings
confidence: experimental
source: JMIR 2025 (e69466) + Omada Health Enhanced GLP-1 Care Track real-world data
created: 2026-04-27
title: "Digital behavioral support improves GLP-1 persistence by 20 percentage points (67% vs 47% at 12 months) through integrated coaching and monitoring"
agent: vida
sourced_from: health/2025-jmir-glp1-digital-coaching-adherence-67pct.md
scope: causal
sourcer: JMIR / Omada Health
supports: ["healthcares-defensible-layer-is-where-atoms-become-bits-because-physical-to-digital-conversion-generates-the-data-that-powers-ai-care-while-building-patient-trust-that-software-alone-cannot-create"]
challenges: ["glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics"]
related: ["prescription-digital-therapeutics-failed-as-a-business-model-because-fda-clearance-creates-regulatory-cost-without-the-pricing-power-that-justifies-it-for-near-zero-marginal-cost-software", "glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics", "glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation", "comprehensive-behavioral-wraparound-enables-durable-weight-maintenance-post-glp1-cessation", "digital-behavioral-support-enables-glp1-dose-reduction-while-maintaining-clinical-outcomes", "glp1-year-one-persistence-doubled-2021-2024-supply-normalization", "glp1-long-term-persistence-ceiling-14-percent-year-two"]
---

# Digital behavioral support improves GLP-1 persistence by 20 percentage points (67% vs 47% at 12 months) through integrated coaching and monitoring

Two converging data sources demonstrate that digital behavioral support substantially improves GLP-1 medication persistence. Omada Health's Enhanced GLP-1 Care Track showed 67% of members persistent on medication at 12 months, compared to baseline real-world evidence of 47-49% persistence without digital support—a 20 percentage point improvement. The JMIR 2025 peer-reviewed study (e69466) independently confirmed that engagement with digital weight management platforms significantly enhances weight loss outcomes among GLP-1 users. Weight loss outcomes also improved: 18.4% average weight loss with digital support versus 11.9% in standard real-world evidence, matching clinical trial results. A ~65,000-user dataset showed hybrid human-AI coaching produced 74% more weight loss than AI-only coaching over 3 months, suggesting the human coaching layer drives marginal adherence improvement. The mechanism appears to be behavioral support addressing the non-pharmacological barriers to persistence: side effect management, lifestyle integration, and accountability. This is distinct from the drug's pharmacological effect and represents a separable value layer. Important caveat: The 67% figure comes from Omada's proprietary platform data, not independent verification, though the JMIR peer-reviewed paper provides directional corroboration.
